← Leaderboards
Kerry L. Burnstein
University Of Miami School Of Medicine
$4,138,515
Attributed
$4,138,515
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $321.6K · FY2005–25$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,138,515 · 7
VA$0 · 2
By mechanism
R01$3,210,182 · 3
P30$629,565 · 3
R21$298,768 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Kenneth W. Goodman$648,721
- Mustafa Tekin$15,488,636
Others in their field
Top investigators on “Androgen Receptor”
- Susan E. Hankinson · University Of Massachusetts Amherst$24,278,267
- Diane E Merry · Thomas Jefferson University$17,810,180
- Charles L Sawyers · Sloan-Kettering Inst Can Research$17,232,913
- Richard D Schulick · Johns Hopkins University$17,086,121
- Shalendar Bhasin · La Biomed Res Inst/ Harbor Ucla Med Ctr$16,194,198
- Xiaoqi Liu · Harvard University$15,300,481
Research focus
Androgen ReceptorMalignant Neoplasm Of ProstateMemberProstate Cancer TherapyLigandsMalignant NeoplasmsPharmaceutical PreparationsBaseGrowthUniversitiesResearch PersonnelHealth PersonnelEvaluationProteinsTumorMultidisciplinaryPositioning AttributeMessenger RnaAndrogensTherapeutic TargetInnovationClinical TrialsCellsCommunities
Grant awards (31)
Cancer Research Training and Education Coordination$207,411
P30 · FY2025 · CA · contact PI
A Novel Drug Target for Aggressive Prostate Cancer$0
I01 · FY2025 · VA · contact PI
Cancer Research Training and Education Coordination$174,384
P30 · FY2024 · CA · contact PI
A Novel Drug Target for Aggressive Prostate Cancer$0
I01 · FY2024 · VA · contact PI
Cancer Research Career Enhancement and Related Activities$52,836
P30 · FY2023 · CA · contact PI
Covid-19: Fast-tracking treatment by exploiting the steroid hormone receptor/TMPRSS2 axis$0
I01 · FY2023 · VA · contact PI
Cancer Research Career Enhancement and Related Activities$51,292
P30 · FY2022 · CA · contact PI
Covid-19: Fast-tracking treatment by exploiting the steroid hormone receptor/TMPRSS2 axis$0
I01 · FY2022 · VA · contact PI
Cancer Research Career Enhancement and Related Activities$48,351
P30 · FY2021 · CA · contact PI
Covid-19: Fast-tracking treatment by exploiting the steroid hormone receptor/TMPRSS2 axis$0
I01 · FY2021 · VA · contact PI
A Novel Drug Target for Aggressive Prostate Cancer$0
I01 · FY2021 · VA · contact PI
Cancer Research Career Enhancement and Related Activities$48,351
P30 · FY2020 · CA · contact PI
A Novel Drug Target for Aggressive Prostate Cancer$0
I01 · FY2020 · VA · contact PI
Cancer Research Career Enhancement and Related Activities$46,940
P30 · FY2019 · CA · contact PI
A Novel Drug Target for Aggressive Prostate Cancer$0
I01 · FY2019 · VA · contact PI
A Novel Drug Target for Aggressive Prostate Cancer$0
I01 · FY2018 · VA · contact PI
Vav3 Oncogene Potentiation of Androgen Receptor Signaling in Prostate Cancer.$289,549
R01 · FY2013 · CA · contact PI
Vav3 Oncogene Potentiation of Androgen Receptor Signaling in Prostate Cancer.$308,945
R01 · FY2012 · CA · contact PI
Vav3 Oncogene Potentiation of Androgen Receptor Signaling in Prostate Cancer.$312,123
R01 · FY2011 · CA · contact PI
Vav3 Oncogene Potentiation of Androgen Receptor Signaling in Prostate Cancer.$321,650
R01 · FY2010 · CA · contact PI
Vav3 Oncogene Potentiation of Androgen Receptor Signaling in Prostate Cancer.$321,530
R01 · FY2009 · CA · contact PI
Vitamin D Promotes G1 Arrest via Cdk2 Mislocalization$257,436
R01 · FY2007 · CA · contact PI
Vitamin D Promotes G1 Arrest via Cdk2 Mislocalization$265,125
R01 · FY2006 · CA · contact PI
Vitamin D Promotes G1 Arrest via Cdk2 Mislocalization$265,125
R01 · FY2005 · CA
Vitamin D Promotes G1 Arrest via Cdk2 Mislocalization$265,125
R01 · FY2004 · CA
Vav3, a Rho GEF, Stimulates AR Activity and CaP Growth$149,384
R21 · FY2004 · DK
Vav3, a Rho GEF, Stimulates AR Activity and CaP Growth$149,384
R21 · FY2003 · DK
HORMONAL REGULATION OF ANDROGEN RECEPTOR EXPRESSION$197,787
R01 · FY2002 · DK
HORMONAL REGULATION OF ANDROGEN RECEPTOR EXPRESSION$192,026
R01 · FY2001 · DK
HORMONAL REGULATION OF ANDROGEN RECEPTOR EXPRESSION$161,204
R01 · FY2000 · DK
HORMONAL REGULATION OF ANDROGEN RECEPTOR EXPRESSION$52,557
R01 · FY2000 · DK